Wettstein, Dominik J.; Boes, Stefan - In: Health Economics Review 10 (2020) 13, pp. 1-15
Background: The necessity to measure and reward "value for money" of new pharmaceuticals has become central in health policy debates, as much as the requirement to assess the "willingness to pay" for an additional, qualityadjusted life year (QALY). There is a clear need to understand the...
